218 related articles for article (PubMed ID: 16020667)
1. Reversal of cisplatin resistance with a BH3 mimetic, (-)-gossypol, in head and neck cancer cells: role of wild-type p53 and Bcl-xL.
Bauer JA; Trask DK; Kumar B; Los G; Castro J; Lee JS; Chen J; Wang S; Bradford CR; Carey TE
Mol Cancer Ther; 2005 Jul; 4(7):1096-104. PubMed ID: 16020667
[TBL] [Abstract][Full Text] [Related]
2. In vitro effects of the BH3 mimetic, (-)-gossypol, on head and neck squamous cell carcinoma cells.
Oliver CL; Bauer JA; Wolter KG; Ubell ML; Narayan A; O'Connell KM; Fisher SG; Wang S; Wu X; Ji M; Carey TE; Bradford CR
Clin Cancer Res; 2004 Nov; 10(22):7757-63. PubMed ID: 15570010
[TBL] [Abstract][Full Text] [Related]
3. Targeting apoptosis to overcome cisplatin resistance: a translational study in head and neck cancer.
Bauer JA; Kumar B; Cordell KG; Prince ME; Tran HH; Wolf GT; Chepeha DB; Teknos TN; Wang S; Eisbruch A; Tsien CI; Urba SG; Worden FP; Lee J; Griffith KA; Taylor JM; D'Silva N; Wang SJ; Wolter KG; Henson B; Fisher SG; Carey TE; Bradford CR
Int J Radiat Oncol Biol Phys; 2007; 69(2 Suppl):S106-8. PubMed ID: 17848273
[TBL] [Abstract][Full Text] [Related]
4. P53 mutation correlates with cisplatin sensitivity in head and neck squamous cell carcinoma lines.
Bradford CR; Zhu S; Ogawa H; Ogawa T; Ubell M; Narayan A; Johnson G; Wolf GT; Fisher SG; Carey TE
Head Neck; 2003 Aug; 25(8):654-61. PubMed ID: 12884349
[TBL] [Abstract][Full Text] [Related]
5. Over-expression of BAG-1 in head and neck squamous cell carcinomas (HNSCC) is associated with cisplatin-resistance.
Liu S; Ren B; Gao H; Liao S; Zhai YX; Li S; Su XJ; Jin P; Stroncek D; Xu Z; Zeng Q; Li Y
J Transl Med; 2017 Sep; 15(1):189. PubMed ID: 28877725
[TBL] [Abstract][Full Text] [Related]
6. Chemoresistance is associated with increased cytoprotective autophagy and diminished apoptosis in bladder cancer cells treated with the BH3 mimetic (-)-Gossypol (AT-101).
Mani J; Vallo S; Rakel S; Antonietti P; Gessler F; Blaheta R; Bartsch G; Michaelis M; Cinatl J; Haferkamp A; Kögel D
BMC Cancer; 2015 Apr; 15():224. PubMed ID: 25885284
[TBL] [Abstract][Full Text] [Related]
7. Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53.
Gadhikar MA; Sciuto MR; Alves MV; Pickering CR; Osman AA; Neskey DM; Zhao M; Fitzgerald AL; Myers JN; Frederick MJ
Mol Cancer Ther; 2013 Sep; 12(9):1860-73. PubMed ID: 23839309
[TBL] [Abstract][Full Text] [Related]
8. A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53(mut) exhibits ATP-binding cassette transporter upregulation and high glutathione levels.
Tonigold M; Rossmann A; Meinold M; Bette M; Märken M; Henkenius K; Bretz AC; Giel G; Cai C; Rodepeter FR; Beneš V; Grénman R; Carey TE; Lage H; Stiewe T; Neubauer A; Werner JA; Brendel C; Mandic R
J Cancer Res Clin Oncol; 2014 Oct; 140(10):1689-704. PubMed ID: 24913304
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin-induced apoptosis in non-small-cell lung cancer cells is dependent on Bax- and Bak-induction pathway and synergistically activated by BH3-mimetic ABT-263 in p53 wild-type and mutant cells.
Matsumoto M; Nakajima W; Seike M; Gemma A; Tanaka N
Biochem Biophys Res Commun; 2016 Apr; 473(2):490-6. PubMed ID: 26996126
[TBL] [Abstract][Full Text] [Related]
10. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer.
Friedman J; Nottingham L; Duggal P; Pernas FG; Yan B; Yang XP; Chen Z; Van Waes C
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6568-78. PubMed ID: 18006756
[TBL] [Abstract][Full Text] [Related]
11. Liposome encapsulated curcumin-difluorinated (CDF) inhibits the growth of cisplatin resistant head and neck cancer stem cells.
Basak SK; Zinabadi A; Wu AW; Venkatesan N; Duarte VM; Kang JJ; Dalgard CL; Srivastava M; Sarkar FH; Wang MB; Srivatsan ES
Oncotarget; 2015 Jul; 6(21):18504-17. PubMed ID: 26098778
[TBL] [Abstract][Full Text] [Related]
12. Wild-type p53 reactivation by small-molecule Minnelide™ in human papillomavirus (HPV)-positive head and neck squamous cell carcinoma.
Caicedo-Granados E; Lin R; Fujisawa C; Yueh B; Sangwan V; Saluja A
Oral Oncol; 2014 Dec; 50(12):1149-56. PubMed ID: 25311433
[TBL] [Abstract][Full Text] [Related]
13. Targeting antiapoptotic Bcl-2 family members with cell-permeable BH3 peptides induces apoptosis signaling and death in head and neck squamous cell carcinoma cells.
Li R; Boehm AL; Miranda MB; Shangary S; Grandis JR; Johnson DE
Neoplasia; 2007 Oct; 9(10):801-11. PubMed ID: 17971900
[TBL] [Abstract][Full Text] [Related]
14. Proapoptotic protein Smac mediates apoptosis in cisplatin-resistant ovarian cancer cells when treated with the anti-tumor agent AT101.
Hu W; Wang F; Tang J; Liu X; Yuan Z; Nie C; Wei Y
J Biol Chem; 2012 Jan; 287(1):68-80. PubMed ID: 22052903
[TBL] [Abstract][Full Text] [Related]
15. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
16. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
17. Cisplatin-induced growth arrest of head and neck cancer cells correlates with increased expression of p16 and p53.
Yip HT; Chopra R; Chakrabarti R; Veena MS; Ramamurthy B; Srivatsan ES; Wang MB
Arch Otolaryngol Head Neck Surg; 2006 Mar; 132(3):317-26. PubMed ID: 16549753
[TBL] [Abstract][Full Text] [Related]
18. Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
Nishimura K; Tsuchiya Y; Okamoto H; Ijichi K; Gosho M; Fukayama M; Yoshikawa K; Ueda H; Bradford CR; Carey TE; Ogawa T
Br J Cancer; 2014 Aug; 111(4):799-806. PubMed ID: 25032734
[TBL] [Abstract][Full Text] [Related]
19. Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer.
Zerp SF; Stoter TR; Hoebers FJ; van den Brekel MW; Dubbelman R; Kuipers GK; Lafleur MV; Slotman BJ; Verheij M
Radiat Oncol; 2015 Jul; 10():158. PubMed ID: 26223311
[TBL] [Abstract][Full Text] [Related]
20. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
